following a full submission assessed under the end of life and orphan equivalent medicine process:
amivantamab (Rybrevant®) is not recommended for use within NHSScotland.
Indication under review: in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon20 insertion mutations.
In a phase III study of patients with locally advanced or metastatic NSCLC with EGFR Exon20 insertion mutations, the addition of amivantamab to carboplatin plus pemetrexed significantly improved progression-free survival.
The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- amivantamab (Rybrevant)
- SMC ID:
- SMC2758
- Indication:
In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon20 insertion mutations.
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 07 July 2025